Skip to main content
Top
Published in: Medical Oncology 1/2013

01-03-2013 | Original Paper

Decreased expression of light chain 3 (LC3) increased the risk of distant metastasis in triple-negative breast cancer

Authors: Jie-Hua He, Rong-Zhen Luo, Mu-Yan Cai, Mei Li, Jia-Bing Lu, Zhong-Yu Yuan

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

The aim of this study was to evaluate the prognostic value of light chain 3 (LC3) expression in triple-negative breast cancer (TNBC) and describe the association of LC3 expression with the occurrence of metastasis. LC3 expression in tissue microarray was evaluated by immunohistochemistry in 163 patients with TNBC. The prognostic value of LC3 expression was assessed by a Cox regression model adjusted for clinical characteristics. Low LC3 expression in TNBC was observed in 56 (34.4 %) of 163 TNBC. Low LC3 expression significantly correlated with a higher risk of distant metastasis, rather than locoregional relapse. The 10-year distant metastases-free survival for LC3-negative and LC3-positive patients was 57.2 and 95.1 %, respectively (p < 0.0001). Accordingly, a significant correlation was found between LC3 expression and disease-free survival (DFS) and overall survival (OS). Multivariate analysis indicated that LC3 negative was a significant independent prognostic factor of DFS (p = 0.019), but not for OS (p = 0.545) in all patients. Our results suggested that expression of LC3 in TNBC was associated with higher distant metastases. This finding could open new avenues for the development of novel therapy strategies to TNBC.
Literature
1.
go back to reference Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.PubMedCrossRef Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.PubMedCrossRef
2.
go back to reference Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.PubMedCrossRef Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.PubMedCrossRef
3.
go back to reference Tischkowitz M, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134.PubMedCrossRef Tischkowitz M, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134.PubMedCrossRef
4.
go back to reference Bauer KR, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721–8.PubMedCrossRef Bauer KR, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721–8.PubMedCrossRef
5.
go back to reference Scherz-Shouval R, et al. p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci USA. 2010;107:18511–6.PubMedCrossRef Scherz-Shouval R, et al. p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci USA. 2010;107:18511–6.PubMedCrossRef
6.
go back to reference Cheong H, et al. Biochemical methods to monitor autophagy-related processes in yeast. Met Enzymol. 2008;451:1–26.CrossRef Cheong H, et al. Biochemical methods to monitor autophagy-related processes in yeast. Met Enzymol. 2008;451:1–26.CrossRef
7.
go back to reference Eskelinen EL, et al. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta. 2009;1793(4):664–73.PubMedCrossRef Eskelinen EL, et al. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta. 2009;1793(4):664–73.PubMedCrossRef
8.
go back to reference Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4(2):151–75.PubMed Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4(2):151–75.PubMed
9.
go back to reference Kuma A, et al. LC3, an autophagosome marker, can be incorporated into protein aggregates independent of autophagy: caution in the interpretation of LC3 localization. Autophagy. 2007;3(4):323–8.PubMed Kuma A, et al. LC3, an autophagosome marker, can be incorporated into protein aggregates independent of autophagy: caution in the interpretation of LC3 localization. Autophagy. 2007;3(4):323–8.PubMed
10.
go back to reference Furuya D, et al. Beclin 1 augmented cis-diamminedichloroplatinum induced apoptosis via enhancing caspase-9 activity. Exp Cell Res. 2005;307(1):26–40.PubMedCrossRef Furuya D, et al. Beclin 1 augmented cis-diamminedichloroplatinum induced apoptosis via enhancing caspase-9 activity. Exp Cell Res. 2005;307(1):26–40.PubMedCrossRef
11.
go back to reference Ahn CH, et al. Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers. APMIS. 2007;115(12):1344–9.PubMedCrossRef Ahn CH, et al. Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers. APMIS. 2007;115(12):1344–9.PubMedCrossRef
12.
go back to reference Kondo Y, et al. The role of autophagy in cancer development and response to therapy. Nature reviews. Cancer. 2005;5(9):726–34.PubMed Kondo Y, et al. The role of autophagy in cancer development and response to therapy. Nature reviews. Cancer. 2005;5(9):726–34.PubMed
13.
go back to reference Liang XH, et al. Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. Cancer Res. 2001;61:3443–9.PubMed Liang XH, et al. Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. Cancer Res. 2001;61:3443–9.PubMed
14.
go back to reference Sivridis E, et al. LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas. Am J Pathol. 2010;176(5):2477–89.PubMedCrossRef Sivridis E, et al. LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas. Am J Pathol. 2010;176(5):2477–89.PubMedCrossRef
15.
go back to reference He J, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29(2):406–10.PubMedCrossRef He J, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29(2):406–10.PubMedCrossRef
17.
go back to reference Shintani T, et al. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990–5.PubMedCrossRef Shintani T, et al. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990–5.PubMedCrossRef
18.
go back to reference Klionsky DJ, et al. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717–21.PubMedCrossRef Klionsky DJ, et al. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717–21.PubMedCrossRef
19.
go back to reference Giatromanolaki A, et al. Tumour angiogenesis: vascular growth and survival. APMIS. 2004;112(7–8):431–40.PubMedCrossRef Giatromanolaki A, et al. Tumour angiogenesis: vascular growth and survival. APMIS. 2004;112(7–8):431–40.PubMedCrossRef
20.
go back to reference Martinet W, et al. Detection of autophagy in tissue by standard immunohistochemistry: possibilities and limitations. Autophagy. 2006;2:55–7.PubMed Martinet W, et al. Detection of autophagy in tissue by standard immunohistochemistry: possibilities and limitations. Autophagy. 2006;2:55–7.PubMed
21.
go back to reference Fulford LG, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22–34.PubMedCrossRef Fulford LG, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22–34.PubMedCrossRef
22.
go back to reference Livasy CA, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264–71.PubMedCrossRef Livasy CA, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264–71.PubMedCrossRef
23.
go back to reference Kabeya Y, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720–8.PubMedCrossRef Kabeya Y, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720–8.PubMedCrossRef
24.
go back to reference He H, et al. Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B. J Bio Chem. 2003;278(31):29278–87.CrossRef He H, et al. Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B. J Bio Chem. 2003;278(31):29278–87.CrossRef
25.
go back to reference Sato K, et al. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res. 2007;67(20):9677–84.PubMedCrossRef Sato K, et al. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res. 2007;67(20):9677–84.PubMedCrossRef
26.
go back to reference Berardi DE, et al. Autophagy: friend or foe in breast cancer development, progression, and treatment. Int J Breast Cancer. 2011;59:509–12. Berardi DE, et al. Autophagy: friend or foe in breast cancer development, progression, and treatment. Int J Breast Cancer. 2011;59:509–12.
27.
go back to reference Shen Y, et al. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy. 2008;4:1067–8.PubMed Shen Y, et al. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy. 2008;4:1067–8.PubMed
28.
go back to reference Jiang ZF, et al. Decreased expression of Beclin-1 and LC3 in human lung cancer. Mol Biol Rep. 2012;39:259–67.PubMedCrossRef Jiang ZF, et al. Decreased expression of Beclin-1 and LC3 in human lung cancer. Mol Biol Rep. 2012;39:259–67.PubMedCrossRef
29.
go back to reference Marino G, et al. Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/autophagin-3. J Biol Chem. 2007;282(25):18573–83.PubMedCrossRef Marino G, et al. Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/autophagin-3. J Biol Chem. 2007;282(25):18573–83.PubMedCrossRef
30.
go back to reference Fujii S, et al. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 2008;99:1813–9.PubMedCrossRef Fujii S, et al. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 2008;99:1813–9.PubMedCrossRef
31.
go back to reference Zhu W, et al. Expression of Beclin 1 and LC3 in FIGO stage I-II cervical squamous cell carcinoma and relationship to survival. Tumour Biol. 2012;33:1653–9.PubMedCrossRef Zhu W, et al. Expression of Beclin 1 and LC3 in FIGO stage I-II cervical squamous cell carcinoma and relationship to survival. Tumour Biol. 2012;33:1653–9.PubMedCrossRef
32.
go back to reference Liang XH, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672–6.PubMedCrossRef Liang XH, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672–6.PubMedCrossRef
Metadata
Title
Decreased expression of light chain 3 (LC3) increased the risk of distant metastasis in triple-negative breast cancer
Authors
Jie-Hua He
Rong-Zhen Luo
Mu-Yan Cai
Mei Li
Jia-Bing Lu
Zhong-Yu Yuan
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0468-0

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine